Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAR-MOG trial in MOG antibody-associated disease
ACTRN12624001258549Phase 3Recruiting
- Sponsor
- University of Sydney
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of prednisone and rituximab in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) (4 arms), sponsored by University of Sydney. Primary endpoint: Time to first centrally adjudicated relapse. Started May 2025; status: recruiting.
02
Drugs
prednisonerituximab
03
Conditions
myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)
Beyond the preview
Go deeper on ACTRN12624001258549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624001258549.